Skip to main
APDN
APDN logo

APDN Stock Forecast & Price Target

APDN Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Applied DNA Sciences Inc. anticipates significant revenue growth in the latter half of calendar 2024, primarily fueled by increased customer orders for critical mRNA therapeutic starting materials. The company has demonstrated consecutive quarterly revenue growth, with total revenue rising to $891 million in F1Q24, reflecting strong demand and the advancement of its first-phase GMP production slated for the first half of 2024. Additionally, the innovative Linea IVT platform enhances mRNA production efficiency and safety, positioning the company favorably within the biotechnology industry and supporting its commercial adoption.

Bears say

Applied DNA Sciences Inc. has experienced a significant downturn in its financial performance, reporting a total revenue of $0.8 million for F4Q23, which reflects a staggering 78% year-over-year decline. This continued decline in revenue, driven primarily by reductions in COVID-19 testing services and cotton DNA tagging revenue, indicates persistent challenges in its core business segments. Furthermore, the company reported a net loss of $3.6 million in F4Q23 and a total annual revenue of $13.4 million for FY2023, which marks a 26% year-over-year decline, compounding concerns about its growth strategy and operational progress amidst regulatory hurdles.

APDN has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Applied DNA Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Applied DNA Sciences (APDN) Forecast

Analysts have given APDN a Buy based on their latest research and market trends.

According to 4 analysts, APDN has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Applied DNA Sciences (APDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.